Published SYMBYX Research
Trial Location
Research Paper
Publication links
Sydney, Australia
Improvements in clinical signs and symptoms of Parkinson’s disease using photobiomodulation: a five-year follow-up
BMC Neurology, October 9, 2024
Read Here
Adelaide, Australia
Improvements in clinical signs of Parkinson’s disease using photobiomodulation: a prospective proof-of-concept study.
BMC Neurology, July 2, 2021
Read Here
Sydney, Australia
Remote Photobiomodulation Treatment for the Clinical Signs of Parkinson’s Disease: A Case Series Conducted During COVID-19.
PBM, Photomedicine, and Laser Surgery, December 16, 2021
Read Here
Adelaide, Australia
Microbiome Changes in Humans with Parkinson’s Disease after Photobiomodulation Therapy: A Retrospective Study.
Journal of Personalised Medicine, January 5, 2022
Read Here
Sydney, Australia
Photophysical Mechanisms of Photobiomodulation Therapy as Precision Medicine.
Biomedicines
Read Here
Brisbane, Australia
A Holistic Perspective on How Photobiomodulation May Influence Fatigue, Pain, and Depression in Inflammatory Bowel Disease: Beyond Molecular Mechanisms.
Biomedicines
Read Here
Sydney, Australia
A Randomized Placebo-Controlled Study of a Transcranial Photobiomodulation Helmet in Parkinson’s Disease: Post-Hoc Analysis of Motor Outcomes. First 12 weeks results.
Journal of Clinical Medicine
Read Here
Sydney, Australia
A novel transcranial photobiomodulation device to address motor signs of Parkinson's disease: a parallel randomised feasibility study.
THE LANCET eClinicalMedicine
Read Here
SYMBYX Research Currently Underway
Trial Location
Brief of Research
Scientific Partners
Status
Press Release
Hamilton, Canada (2023)
A clinical trial is underway to assess the effectiveness of the SYMBYX system, which consists of the PDCare laser and the SYMBYX Neuro helmet, in treating motor and non motor symptoms of Parkinson’s disease. The study has been designed as a randomized controlled trial, including a placebo group, and will involve 60 participants who will receive treatment with either the SYMBYX system or a placebo. Participants in the trial will receive exercise physiotherapy as well as light therapy. The aim of the trial is to determine whether the SYMBYX system is an effective treatment option for Parkinson’s disease symptoms.
Saltmarche Associates; Gaitway Neurophysio
Study is almost complete
March 31, 2022
Read Here
Adelaide, Australia (2023)
Cinical trial is examining the effectiveness of the SYMBYX system, consisting of the PDCare laser and the Neuro helmet, in treating non-motor symptoms of Parkinson’s disease. The study is designed as a randomized controlled trial, including a placebo group, and involves 36 participants who will receive either the SYMBYX system or a placebo treatment. The aim of the trial is to assess whether the SYMBYX system is a viable treatment option for non-motor symptoms associated with Parkinson’s disease.
Flinders University, Adelaide. Parkinson’s SA
Study is almost complete
January 6, 2021
Read Here
Brisbane, Australia (2023)
A clinical trial is being conducted to test the effectiveness of the SYMBYX laser light in reducing symptoms associated with Inflammatory Bowel Disease (IBD) in young adults. The study aims to evaluate the efficacy of the treatment and determine whether the SYMBYX laser light can be used as a potential therapeutic option for managing IBD symptoms in this population.
Mater Research Hospital, Brisbane
Study is underway
June 2, 2022
Read Here
EXPLORE ARTICLES
Stay connected with SYMBYX / next-generation treatments meticulously supported by science.
